Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Ketamine for the Treatment of Depression in Parkinson's Disease


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT04944017

Organisation Name: Yale University

Overal Status: Not yet recruiting

Start Date: August 2021

Last Update: June 29, 2021

Lead Sponsor: Yale University

Brief Summary: The main purpose of this study is to examine the efficacy, safety and mechanistic underpinnings of a repeated dosing ketamine infusion paradigm compared to placebo in individuals with PD.

A subset of participants in each arm will undergo baseline and post-treatment PET and fMRI scans, to examine whether changes in synaptic density and reorganization of functional networks underlie ketamine's putative antidepressant effects in PD.

Conditions:
  • Parkinson's Disease
  • Depression


Total execution time in seconds: 0.17183494567871